Ökat söktryck hos Emea

A crash course in IP strategy

"Publish, publish, publish!" Sound familiar? So to meet the researcher's wishes, do you scribble a patent application with lipstick on a napkin and send it in? At the seminar Patent Strategies in the Biotech Company, you will have the chance to find out why this might not be the best idea.

BMAs: Run your own business

After graduation you must decide: be an employee or start your own business. This is not really the situation for BMAs today, but a collaborative project between Swedish public actors and some companies aims to change that and make entrepreneurs of BMAs.

Hey Johannes Hedman...

... graduate of SKL and LTH, who has improved a method of forensic analysis

Age essential when testing drugs

Anders Rane has been arguing that genes and age are both important factors in understanding how medicines affect individuals. Only last year, the EU established regulations stating that pharmaceuticals must be tested for children as well as for adults.

From planning stage to handshake

"Partnering is an effective tool to get in touch with the decision makers high up in an organization's administration," says Camilla Huse Bondeson at Conlega. And according to her, rigorous planning is the way to succeed.

How to get the most out of the fair

Ny professor startskott för LiU-satsning

May Griffith är ny professor i regenerativ medicin på Linköpings universitet och hennes kompetens blir startskottet för universitetets satsning på området.

180 miljoner till nanoforskning

En stor satsning från det europeiska programmet Euro Nano Med ska finansiera två svenska nanoforskningsprojekt. Chalmers tekniska högskola, Linköpings universitet, Umeå universitet och Vironova får vara med och dela på pengarna.

With their hands on the legal levers

It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.

The winner of the race

She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.

Genförändring orsakar sällsynta sjukdomar

Ny forskning från Umeå universitet kastar ljus över orsaken till tre ovanliga skelettsjukdomar.

Rekordmånga vill ha Formaspengar

Drygt 1300 ansökningar har lämnats in till årets stora utlysning från Forskningsrådet Formas. I november meddelas vilka som får pengar.

Hansa Medical vill ta in pengar

Årsstämman om en månad ska ta ställning till styrelsens förslag om nyemission och en rad andra förändringar.

Nobelpristagare blir hedersdoktor

Den 29 maj promoveras två nya hedersdoktorer vid Medicinska fakulteten, Lunds universitet.

Svensk forskning halkar bakåt

Den svenska oorganiska kemiforskningen tappar mark i den internationella konkurrensen. Det hävdar en panel internationella experter i en ny granskningsrapport.

Swedish top scientists to EMBO

Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.

Re-painting the big pig-ture

Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.

Athera signs production partnership

The companys novel cardiovascular product will be manufactured in Germany.

Test if you carry the fat virus

In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.

Pfizer lays a chunky bid on Wyeth

that may lead to lay-offs of some 8,000 persons.

New member to Active board

The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.

Fusion between pharma giants?

It is rumoured that a fusion between Pfizer and Wyeth is in the process of happening.

EUR 2 million for peanut allergies

ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.